Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024Third Quarter 2024 • Total revenue increased 33 per cent, 39 per cent at constant exchange rates, (CER)1, to SEK 6,894 M (5,168) • Haematology revenue increased 18 per cent at CER to SEK 4,000 M (3,484), mainly driven by strong sales of Doptelet[®] of SEK 1,039 M (650), sales of Aspaveli[®]/Empaveli[®] of SEK 270 M (169) and launch sales of Altuvoct[®] of SEK 129 M (—) • Immunology revenue increased 96 per cent at CER to SEK 2,583 M (1,400), driven by strong